ID   RB_HUMAN                Reviewed;         928 AA.
AC   P06400; A8K5E3; P78499; Q5VW46; Q8IZL4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 2.
DT   22-JUL-2015, entry version 209.
DE   RecName: Full=Retinoblastoma-associated protein;
DE   AltName: Full=p105-Rb;
DE   AltName: Full=pRb;
DE            Short=Rb;
DE   AltName: Full=pp110;
GN   Name=RB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3657987; DOI=10.1038/329642a0;
RA   Lee W.-H., Shew J.-Y., Hong F.D., Sery T.W., Donoso L.A.,
RA   Young L.-J.S., Bookstein R., Lee E.Y.-H.P.;
RT   "The retinoblastoma susceptibility gene encodes a nuclear
RT   phosphoprotein associated with DNA binding activity.";
RL   Nature 329:642-645(1987).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=3823889; DOI=10.1126/science.3823889;
RA   Lee W.-H., Bookstein R., Hong F.D., Young L.-J., Shew J.-Y.,
RA   Lee E.Y.-H.P.;
RT   "Human retinoblastoma susceptibility gene: cloning, identification,
RT   and sequence.";
RL   Science 235:1394-1399(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3480530; DOI=10.1073/pnas.84.24.9059;
RA   Friend S.H., Horowitz J.M., Gerber M.R., Wang X.-F., Bogenmann E.,
RA   Li F.P., Weinberg R.A.;
RT   "Deletions of a DNA sequence in retinoblastomas and mesenchymal
RT   tumors: organization of the sequence and its encoded protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9059-9063(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2701949; DOI=10.1016/0378-1119(89)90256-4;
RA   McGee T.L., Yandell D.W., Dryja T.P.;
RT   "Structure and partial genomic sequence of the human retinoblastoma
RT   susceptibility gene.";
RL   Gene 80:119-128(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Carcinoma;
RX   PubMed=1352398;
RA   Hogg A., Onadim Z., Baird P.N., Cowell J.K.;
RT   "Detection of heterozygous mutations in the RB1 gene in retinoblastoma
RT   patients using single-strand conformation polymorphism analysis and
RT   polymerase chain reaction sequencing.";
RL   Oncogene 7:1445-1451(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7902321; DOI=10.1006/geno.1993.1368;
RA   Toguchida J., McGee T.L., Paterson J.C., Eagle J.R., Tucker S.,
RA   Yandell D.W., Dryja T.P.;
RT   "Complete genomic sequence of the human retinoblastoma susceptibility
RT   gene.";
RL   Genomics 17:535-543(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-436 AND GLY-525.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45.
RX   PubMed=2717184;
RA   T'Ang A., Wu K.J., Hashimoto T., Liu W.Y., Takahashi R., Shi X.H.,
RA   Mihara K., Zhang F.H., Chen Y.Y., Du C., Qian J., Lin Y.G.,
RA   Murphree A.L., Qiu W.R., Thompson T., Benedict W.F., Fung Y.K.T.;
RT   "Genomic organization of the human retinoblastoma gene.";
RL   Oncogene 4:401-407(1989).
RN   [13]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN AND HPV E7 PROTEIN.
RX   PubMed=1316611; DOI=10.1073/pnas.89.10.4549;
RA   Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M.,
RA   Phelps W.C., Nevins J.R.;
RT   "Adenovirus E1A, simian virus 40 tumor antigen, and human
RT   papillomavirus E7 protein share the capacity to disrupt the
RT   interaction between transcription factor E2F and the retinoblastoma
RT   gene product.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4549-4553(1992).
RN   [14]
RP   PROTEIN SEQUENCE OF 47-65, AND INVOLVEMENT IN RETINOBLASTOMA.
RX   PubMed=7881418; DOI=10.1093/hmg/3.12.2187;
RA   Lohmann D.R., Brandt B., Hopping W., Passarge E., Horsthemke B.;
RT   "Spectrum of small length germline mutations in the RB1 gene.";
RL   Hum. Mol. Genet. 3:2187-2193(1994).
RN   [15]
RP   PHOSPHORYLATION BY CDK6.
RX   PubMed=8114739;
RA   Meyerson M., Harlow E.;
RT   "Identification of G1 kinase activity for cdk6, a novel cyclin D
RT   partner.";
RL   Mol. Cell. Biol. 14:2077-2086(1994).
RN   [16]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN.
RX   PubMed=2839300; DOI=10.1016/0092-8674(88)90559-4;
RA   Decaprio J.A., Ludlow J.W., Figge J., Shew J.-Y., Huang C.-M.,
RA   Lee W.-H., Marsilio E., Paucha E., Livingston D.M.;
RT   "SV40 large tumor antigen forms a specific complex with the product of
RT   the retinoblastoma susceptibility gene.";
RL   Cell 54:275-283(1988).
RN   [17]
RP   INVOLVEMENT IN RETINOBLASTOMA.
RX   PubMed=3413073; DOI=10.1073/pnas.85.16.6017;
RA   Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G.,
RA   Lee W.-H.;
RT   "Molecular mechanism of retinoblastoma gene inactivation in
RT   retinoblastoma cell line Y79.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988).
RN   [18]
RP   PHOSPHORYLATION AT SER-249; THR-252; THR-373; SER-807 AND SER-811.
RX   PubMed=1756735;
RA   Lees J.A., Buchkovich K.J., Marshak D.R., Anderson C.W., Harlow E.;
RT   "The retinoblastoma protein is phosphorylated on multiple sites by
RT   human cdc2.";
RL   EMBO J. 10:4279-4290(1991).
RN   [19]
RP   INTERACTION WITH KDM5A AND ARID4A.
RX   PubMed=8414517;
RA   Fattaey A.R., Helin K., Dembski M.S., Dyson N., Harlow E.,
RA   Vuocolo G.A., Hanobik M.G., Haskell K.M., Oliff A., Defeo-Jones D.,
RA   Jones R.E.;
RT   "Characterization of the retinoblastoma binding proteins RBP1 and
RT   RBP2.";
RL   Oncogene 8:3149-3156(1993).
RN   [20]
RP   INTERACTION WITH THOC1.
RX   PubMed=7525595; DOI=10.1083/jcb.127.3.609;
RA   Durfee T., Mancini M.A., Jones D., Elledge S.J., Lee W.H.;
RT   "The amino-terminal region of the retinoblastoma gene product binds a
RT   novel nuclear matrix protein that co-localizes to centers for RNA
RT   processing.";
RL   J. Cell Biol. 127:609-622(1994).
RN   [21]
RP   INTERACTION WITH KDM5A.
RX   PubMed=7935440;
RA   Kim Y.W., Otterson G.A., Kratzke R.A., Coxon A.B., Kaye F.J.;
RT   "Differential specificity for binding of retinoblastoma binding
RT   protein 2 to RB, p107, and TATA-binding protein.";
RL   Mol. Cell. Biol. 14:7256-7264(1994).
RN   [22]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=8892909;
RA   Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.S.;
RT   "The human cytomegalovirus IE1-72 protein interacts with the cellular
RT   p107 protein and relieves p107-mediated transcriptional repression of
RT   an E2F-responsive promoter.";
RL   J. Virol. 70:7867-7877(1996).
RN   [23]
RP   INTERACTION WITH ARID3B.
RX   PubMed=10446990;
RA   Numata S., Claudio P.P., Dean C., Giordano A., Croce C.M.;
RT   "Bdp, a new member of a family of DNA-binding proteins, associates
RT   with the retinoblastoma gene product.";
RL   Cancer Res. 59:3741-3747(1999).
RN   [24]
RP   PHOSPHORYLATION AT SER-567 BY CDK2, AND PHOSPHORYLATION BY CDK4 AND
RP   CDK6.
RX   PubMed=10499802; DOI=10.1016/S0092-8674(00)81519-6;
RA   Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C.;
RT   "Cdk phosphorylation triggers sequential intramolecular interactions
RT   that progressively block Rb functions as cells move through G1.";
RL   Cell 98:859-869(1999).
RN   [25]
RP   INTERACTION WITH NDC80.
RX   PubMed=10409732;
RA   Zheng L., Chen Y., Lee W.-H.;
RT   "Hec1p, an evolutionarily conserved coiled-coil protein, modulates
RT   chromosome segregation through interaction with SMC proteins.";
RL   Mol. Cell. Biol. 19:5417-5428(1999).
RN   [26]
RP   INTERACTION WITH NDC80.
RX   PubMed=10779342; DOI=10.1128/MCB.20.10.3529-3537.2000;
RA   Zheng L., Chen Y., Riley D.J., Chen P.-L., Lee W.-H.;
RT   "Retinoblastoma protein enhances the fidelity of chromosome
RT   segregation mediated by hsHec1p.";
RL   Mol. Cell. Biol. 20:3529-3537(2000).
RN   [27]
RP   INTERACTION WITH TAF1.
RX   PubMed=9858607;
RA   Siegert J.L., Robbins P.D.;
RT   "Rb inhibits the intrinsic kinase activity of TATA-binding protein-
RT   associated factor TAFII250.";
RL   Mol. Cell. Biol. 19:846-854(1999).
RN   [28]
RP   INTERACTION WITH E4F1.
RX   PubMed=10869426; DOI=10.1073/pnas.130198397;
RA   Fajas L., Paul C., Zugasti O., Le Cam L., Polanowska J., Fabbrizio E.,
RA   Medema R., Vignais M.-L., Sardet C.;
RT   "pRB binds to and modulates the transrepressing activity of the E1A-
RT   regulated transcription factor p120E4F.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7738-7743(2000).
RN   [29]
RP   INTERACTION WITH EID1.
RX   PubMed=11223246; DOI=10.1016/S0378-1119(00)00585-0;
RA   Wen H., Ao S.;
RT   "Identification and characterization of a novel human cDNA encoding a
RT   21 kDa pRb-associated protein.";
RL   Gene 263:85-92(2001).
RN   [30]
RP   INTERACTION WITH DNMT1.
RX   PubMed=10888886; DOI=10.1038/77124;
RA   Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L.,
RA   Wolffe A.P.;
RT   "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses
RT   transcription from E2F-responsive promoters.";
RL   Nat. Genet. 25:338-342(2000).
RN   [31]
RP   INTERACTION WITH SUV39H1.
RX   PubMed=11484059; DOI=10.1038/35087620;
RA   Nielsen S.J., Schneider R., Bauer U.-M., Bannister A.J., Morrison A.,
RA   O'Carroll D., Firestein R., Cleary M.L., Jenuwein T., Herrera R.E.,
RA   Kouzarides T.;
RT   "Rb targets histone H3 methylation and HP1 to promoters.";
RL   Nature 412:561-565(2001).
RN   [32]
RP   INTERACTION WITH USP4.
RX   PubMed=11571652; DOI=10.1038/sj.onc.1204824;
RA   DeSalle L.M., Latres E., Lin D., Graner E., Montagnoli A., Baker R.T.,
RA   Pagano M., Loda M.;
RT   "The de-ubiquitinating enzyme Unp interacts with the retinoblastoma
RT   protein.";
RL   Oncogene 20:5538-5542(2001).
RN   [33]
RP   INTERACTION WITH AATF.
RX   PubMed=12450794; DOI=10.1016/S1535-6108(02)00182-4;
RA   Bruno T., De Angelis R., De Nicola F., Barbato C., Di Padova M.,
RA   Corbi N., Libri V., Benassi B., Mattei E., Chersi A., Soddu S.,
RA   Floridi A., Passananti C., Fanciulli M.;
RT   "Che-1 affects cell growth by interfering with the recruitment of
RT   HDAC1 by Rb.";
RL   Cancer Cell 2:387-399(2002).
RN   [34]
RP   INTERACTION WITH TMPO-ALPHA AND LMNA.
RX   PubMed=12475961; DOI=10.1091/mbc.E02-07-0450;
RA   Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J.;
RT   "Lamin A/C binding protein LAP2alpha is required for nuclear anchorage
RT   of retinoblastoma protein.";
RL   Mol. Biol. Cell 13:4401-4413(2002).
RN   [35]
RP   INTERACTION WITH SNW1.
RX   PubMed=12466551; DOI=10.1093/nar/gkf658;
RA   Prathapam T., Kuhne C., Banks L.;
RT   "Skip interacts with the retinoblastoma tumor suppressor and inhibits
RT   its transcriptional repression activity.";
RL   Nucleic Acids Res. 30:5261-5268(2002).
RN   [36]
RP   INTERACTION WITH PELP1.
RX   PubMed=12682072; DOI=10.1074/jbc.M212822200;
RA   Balasenthil S., Vadlamudi R.K.;
RT   "Functional interactions between the estrogen receptor coactivator
RT   PELP1/MNAR and retinoblastoma protein.";
RL   J. Biol. Chem. 278:22119-22127(2003).
RN   [37]
RP   FUNCTION IN G0-G1 TRANSITION, AND PHOSPHORYLATION AT SER-807 AND
RP   SER-811 BY CDK3.
RX   PubMed=15084261; DOI=10.1016/S0092-8674(04)00300-9;
RA   Ren S., Rollins B.J.;
RT   "Cyclin C/cdk3 promotes Rb-dependent G0 exit.";
RL   Cell 117:239-251(2004).
RN   [38]
RP   INTERACTION WITH LIN9.
RX   PubMed=15538385; DOI=10.1038/sj.emboj.7600470;
RA   Gagrica S., Hauser S., Kolfschoten I., Osterloh L., Agami R.,
RA   Gaubatz S.;
RT   "Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-
RT   associated protein.";
RL   EMBO J. 23:4627-4638(2004).
RN   [39]
RP   INTERACTION WITH CEBPA.
RX   PubMed=15107404; DOI=10.1101/gad.1183304;
RA   Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.;
RT   "Liver tumors escape negative control of proliferation via PI3K/Akt-
RT   mediated block of C/EBP alpha growth inhibitory activity.";
RL   Genes Dev. 18:912-925(2004).
RN   [40]
RP   INTERACTION WITH LIMD1.
RX   PubMed=15542589; DOI=10.1073/pnas.0407123101;
RA   Sharp T.V., Munoz F., Bourboulia D., Presneau N., Darai E.,
RA   Wang H.-W., Cannon M., Butcher D.N., Nicholson A.G., Klein G.,
RA   Imreh S., Boshoff C.;
RT   "LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded
RT   at chromosome 3p21.3, binds pRB and represses E2F-driven
RT   transcription.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:16531-16536(2004).
RN   [41]
RP   PHOSPHORYLATION AT THR-821 AND THR-826.
RX   PubMed=15809340; DOI=10.1093/jb/mvi050;
RA   Takaki T., Fukasawa K., Suzuki-Takahashi I., Semba K., Kitagawa M.,
RA   Taya Y., Hirai H.;
RT   "Preferences for phosphorylation sites in the retinoblastoma protein
RT   of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro.";
RL   J. Biochem. 137:381-386(2005).
RN   [42]
RP   INTERACTION WITH KDM4A.
RX   PubMed=15927959; DOI=10.1074/jbc.M413687200;
RA   Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S.,
RA   Jingu H., Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F.;
RT   "Functional characterization of JMJD2A, a histone deacetylase- and
RT   retinoblastoma-binding protein.";
RL   J. Biol. Chem. 280:28507-28518(2005).
RN   [43]
RP   INTERACTION WITH KDM5B.
RX   PubMed=15803180; DOI=10.1038/modpathol.3800413;
RA   Roesch A., Becker B., Meyer S., Wild P., Hafner C., Landthaler M.,
RA   Vogt T.;
RT   "Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding
RT   protein downregulated in malignant melanomas.";
RL   Mod. Pathol. 18:1249-1257(2005).
RN   [44]
RP   INTERACTION WITH KDM5A.
RX   PubMed=15949438; DOI=10.1016/j.molcel.2005.05.012;
RA   Benevolenskaya E.V., Murray H.L., Branton P., Young R.A.,
RA   Kaelin W.G. Jr.;
RT   "Binding of pRB to the PHD protein RBP2 promotes cellular
RT   differentiation.";
RL   Mol. Cell 18:623-635(2005).
RN   [45]
RP   INTERACTION WITH PSMA3.
RX   PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017;
RA   Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R.,
RA   Allday M.J., Xiao Z.X.;
RT   "MDM2 promotes proteasome-dependent ubiquitin-independent degradation
RT   of retinoblastoma protein.";
RL   Mol. Cell 20:699-708(2005).
RN   [46]
RP   INTERACTION WITH ZUBR1.
RX   PubMed=16214886; DOI=10.1073/pnas.0507458102;
RA   Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K.,
RA   Sawada J., Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.;
RT   "p600, a unique protein required for membrane morphogenesis and cell
RT   survival.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005).
RN   [47]
RP   INTERACTION WITH KDM5B.
RX   PubMed=16645588; DOI=10.1038/sj.jid.5700324;
RA   Roesch A., Becker B., Schneider-Brachert W., Hagen I., Landthaler M.,
RA   Vogt T.;
RT   "Re-expression of the retinoblastoma-binding protein 2-homolog 1
RT   reveals tumor-suppressive functions in highly metastatic melanoma
RT   cells.";
RL   J. Invest. Dermatol. 126:1850-1859(2006).
RN   [48]
RP   PHOSPHORYLATION AT SER-612 BY CHEK2, AND INTERACTION WITH CHEK2.
RX   PubMed=17380128; DOI=10.1038/sj.emboj.7601652;
RA   Inoue Y., Kitagawa M., Taya Y.;
RT   "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between
RT   pRB and E2F-1 after DNA damage.";
RL   EMBO J. 26:2083-2093(2007).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252 AND
RP   THR-356, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-252;
RP   SER-612; SER-807; SER-811; THR-823 AND THR-826, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-373;
RP   SER-807 AND THR-841, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [54]
RP   METHYLATION AT LYS-860, INTERACTION WITH L3MBTL1, AND MUTAGENESIS OF
RP   LYS-860; LYS-870 AND 873-LYS-LYS-874.
RX   PubMed=20870719; DOI=10.1074/jbc.M110.137612;
RA   Saddic L.A., West L.E., Aslanian A., Yates J.R. III, Rubin S.M.,
RA   Gozani O., Sage J.;
RT   "Methylation of the retinoblastoma tumor suppressor by SMYD2.";
RL   J. Biol. Chem. 285:37733-37740(2010).
RN   [55]
RP   ACETYLATION AT LYS-873 AND LYS-874, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 873-LYS--LYS-874.
RX   PubMed=20940255; DOI=10.1242/jcs.068924;
RA   Pickard A., Wong P.P., McCance D.J.;
RT   "Acetylation of Rb by PCAF is required for nuclear localization and
RT   keratinocyte differentiation.";
RL   J. Cell Sci. 123:3718-3726(2010).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-821 AND THR-826, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [57]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [58]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [60]
RP   METHYLATION AT LYS-810 BY SMYD2.
RX   PubMed=22787429;
RA   Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T.,
RA   Dohmae N., Kogure M., Kang D., Neal D.E., Ponder B.A., Yamaue H.,
RA   Nakamura Y., Hamamoto R.;
RT   "RB1 methylation by SMYD2 enhances cell cycle progression through an
RT   increase of RB1 phosphorylation.";
RL   Neoplasia 14:476-486(2012).
RN   [61]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 378-562.
RX   PubMed=9145110; DOI=10.1038/nsb0597-390;
RA   Kim H.Y., Cho Y.;
RT   "Structural similarity between the pocket region of retinoblastoma
RT   tumour suppressor and the cyclin-box.";
RL   Nat. Struct. Biol. 4:390-395(1997).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 380-785.
RX   PubMed=9495340; DOI=10.1038/36038;
RA   Lee J.O., Russo A.A., Pavletich N.P.;
RT   "Structure of the retinoblastoma tumour-suppressor pocket domain bound
RT   to a peptide from HPV E7.";
RL   Nature 391:859-865(1998).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 860-876 IN COMPLEX WITH
RP   KPNA2.
RX   PubMed=12695505; DOI=10.1074/jbc.M303275200;
RA   Fontes M.R.M., Teh T., Jans D., Brinkworth R.I., Kobe B.;
RT   "Structural basis for the specificity of bipartite nuclear
RT   localization sequence binding by importin-alpha.";
RL   J. Biol. Chem. 278:27981-27987(2003).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 829-874 IN COMPLEX WITH E2F1
RP   AND TFDP1, INTERACTION WITH HETERODIMERIC COMPLEXES CONTAINING TFDP1
RP   AND EITHER E2F1; E2F3; E2F4 OR E2F5, MUTAGENESIS OF THR-821 AND
RP   THR-826, AND PHOSPHORYLATION AT THR-821 AND THR-826.
RX   PubMed=16360038; DOI=10.1016/j.cell.2005.09.044;
RA   Rubin S.M., Gall A.-L., Zheng N., Pavletich N.P.;
RT   "Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism
RT   for phosphorylation-induced E2F release.";
RL   Cell 123:1093-1106(2005).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 380-787 IN COMPLEX WITH
RP   HUMAN ADENOVIRUS E1A PROTEIN.
RX   PubMed=17974914; DOI=10.1101/gad.1590607;
RA   Liu X., Marmorstein R.;
RT   "Structure of the retinoblastoma protein bound to adenovirus E1A
RT   reveals the molecular basis for viral oncoprotein inactivation of a
RT   tumor suppressor.";
RL   Genes Dev. 21:2711-2716(2007).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 52-355, PARTIAL PROTEIN
RP   SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH THOC1
RP   AND GRIP1, AND INTERACTION OF THE UNPHOSPHORYLATED PROTEIN WITH EID1.
RX   PubMed=17996702; DOI=10.1016/j.molcel.2007.08.023;
RA   Hassler M., Singh S., Yue W.W., Luczynski M., Lakbir R.,
RA   Sanchez-Sanchez F., Bader T., Pearl L.H., Mittnacht S.;
RT   "Crystal structure of the retinoblastoma protein N domain provides
RT   insight into tumor suppression, ligand interaction, and holoprotein
RT   architecture.";
RL   Mol. Cell 28:371-385(2007).
RN   [68]
RP   VARIANT RB LEU-567.
RX   PubMed=2594029; DOI=10.1056/NEJM198912213212501;
RA   Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D.,
RA   Little J.B., McConkie-Rosell A., Buckley E., Dryja T.P.;
RT   "Oncogenic point mutations in the human retinoblastoma gene: their
RT   application to genetic counseling.";
RL   N. Engl. J. Med. 321:1689-1695(1989).
RN   [69]
RP   VARIANT RB TRP-661.
RX   PubMed=1352883; DOI=10.1073/pnas.89.13.6177;
RA   Onadim Z., Hogg A., Baird P.N., Cowell J.K.;
RT   "Oncogenic point mutations in exon 20 of the RB1 gene in families
RT   showing incomplete penetrance and mild expression of the
RT   retinoblastoma phenotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6177-6181(1992).
RN   [70]
RP   VARIANT RB ARG-457.
RX   PubMed=8346255; DOI=10.1073/pnas.90.15.7351;
RA   Hogg A., Bia B., Onadim Z., Cowell J.K.;
RT   "Molecular mechanisms of oncogenic mutations in tumors from patients
RT   with bilateral and unilateral retinoblastoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7351-7355(1993).
RN   [71]
RP   VARIANT RB ARG-530.
RX   PubMed=7704558;
RA   Cowell J.K., Smith T., Bia B.;
RT   "Frequent constitutional C to T mutations in CGA-arginine codons in
RT   the RB1 gene produce premature stop codons in patients with bilateral
RT   (hereditary) retinoblastoma.";
RL   Eur. J. Hum. Genet. 2:281-290(1994).
RN   [72]
RP   VARIANTS RB ASN-480 DEL AND TRP-661.
RX   PubMed=7927327; DOI=10.1007/BF00201591;
RA   Lohmann D.R., Brandt B., Hoepping W., Passarge E., Horsthemke B.;
RT   "Distinct RB1 gene mutations with low penetrance in hereditary
RT   retinoblastoma.";
RL   Hum. Genet. 94:349-354(1994).
RN   [73]
RP   VARIANTS RB GLN-72; TYR-549 AND LYS-803.
RX   PubMed=8605116; DOI=10.1002/gcc.2870140406;
RA   Liu Z., Song Y., Bia B., Cowell J.K.;
RT   "Germline mutations in the RB1 gene in patients with hereditary
RT   retinoblastoma.";
RL   Genes Chromosomes Cancer 14:277-284(1995).
RN   [74]
RP   VARIANTS RB THR-185; PRO-635; GLU-654 AND PRO-685.
RX   PubMed=7795591; DOI=10.1093/hmg/4.3.383;
RA   Blanquet V., Turleau C., Gross-Morand M.S., Senamaud-Beaufort C.,
RA   Doz F., Besmond C.;
RT   "Spectrum of germline mutations in the RB1 gene: a study of 232
RT   patients with hereditary and non hereditary retinoblastoma.";
RL   Hum. Mol. Genet. 4:383-388(1995).
RN   [75]
RP   VARIANTS RB GLY-358; PRO-657 AND TRP-661.
RX   PubMed=8776589; DOI=10.1093/hmg/5.6.755;
RA   Van Orsouw N.J., Li D., van der Vlies P., Scheffer H., Eng C.,
RA   Buys C.H.C.M., Li F.P., Vijg J.;
RT   "Mutational scanning of large genes by extensive PCR multiplexing and
RT   two-dimensional electrophoresis: application to the RB1 gene.";
RL   Hum. Mol. Genet. 5:755-761(1996).
RN   [76]
RP   VARIANTS RB ASP-137 AND TRP-661.
RX   PubMed=9311732; DOI=10.1086/514845;
RA   Lohmann D.R., Gerick M., Brandt B., Oelschlaeger U., Lorenz B.,
RA   Passarge E., Horsthemke B.;
RT   "Constitutional RB1-gene mutations in patients with isolated
RT   unilateral retinoblastoma.";
RL   Am. J. Hum. Genet. 61:282-294(1997).
RN   [77]
RP   VARIANT RB GLN-447.
RX   PubMed=9140452; DOI=10.1016/S0165-4608(96)00387-1;
RA   Mateu E., Sanchez F., Najera C., Beneyto M., Castell V., Hernandez M.,
RA   Serra I., Prieto F.;
RT   "Genetics of retinoblastoma: a study.";
RL   Cancer Genet. Cytogenet. 95:40-50(1997).
RN   [78]
RP   VARIANTS RB LEU-567; PRO-662 AND ARG-712.
RX   PubMed=10671068;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z;
RA   Yilmaz S., Horsthemke B., Lohmann D.R.;
RT   "Twelve novel RB1 gene mutations in patients with hereditary
RT   retinoblastoma.";
RL   Hum. Mutat. 12:434-434(1998).
RN   [79]
RP   VARIANT RB GLU-310.
RX   PubMed=9973307; DOI=10.1086/302254;
RA   Klutz M., Horsthemke B., Lohmann D.R.;
RT   "RB1 gene mutations in peripheral blood DNA of patients with isolated
RT   unilateral retinoblastoma.";
RL   Am. J. Hum. Genet. 64:667-668(1999).
RN   [80]
RP   VARIANTS RB GLY-500 AND GLU-616.
RX   PubMed=11524739; DOI=10.1002/humu.1184;
RA   Yu Y.S., Kim I.-J., Ku J.-L., Park J.-G.;
RT   "Identification of four novel RB1 germline mutations in Korean
RT   retinoblastoma patients.";
RL   Hum. Mutat. 18:252-252(2001).
RN   [81]
RP   VARIANT HIS-173.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: Key regulator of entry into cell division that acts as a
CC       tumor suppressor. Promotes G0-G1 transition when phosphorylated by
CC       CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target
CC       genes. The underphosphorylated, active form of RB1 interacts with
CC       E2F1 and represses its transcription activity, leading to cell
CC       cycle arrest. Directly involved in heterochromatin formation by
CC       maintaining overall chromatin structure and, in particular, that
CC       of constitutive heterochromatin by stabilizing histone
CC       methylation. Recruits and targets histone methyltransferases
CC       SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic
CC       transcriptional repression. Controls histone H4 'Lys-20'
CC       trimethylation. Inhibits the intrinsic kinase activity of TAF1.
CC       Mediates transcriptional repression by SMARCA4/BRG1 by recruiting
CC       a histone deacetylase (HDAC) complex to the c-FOS promoter. In
CC       resting neurons, transcription of the c-FOS promoter is inhibited
CC       by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor
CC       complex. Upon calcium influx, RB1 is dephosphorylated by
CC       calcineurin, which leads to release of the repressor complex (By
CC       similarity). In case of viral infections, interactions with SV40
CC       large T antigen, HPV E7 protein or adenovirus E1A protein induce
CC       the disassembly of RB1-E2F1 complex thereby disrupting RB1's
CC       activity. {ECO:0000250, ECO:0000269|PubMed:15084261}.
CC   -!- SUBUNIT: Interacts with ATAD5. Interacts with PRMT2, CDK1 and CDK2
CC       (By similarity). The hypophosphorylated form interacts with and
CC       sequesters the E2F1 transcription factor. Interacts with
CC       heterodimeric E2F/DP transcription factor complexes containing
CC       TFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. The
CC       unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1,
CC       MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of
CC       TAF1. Interacts with SNW1, AATF, DNMT1, LIN9, LMNA, SUV420H1,
CC       SUV420H2, PELP1, UHRF2 and TMPO-alpha. May interact with NDC80.
CC       Interacts with GRIP1 and UBR4. Interacts with ARID4A and KDM5B.
CC       Interacts with E4F1 and LIMD1. Interacts with SMARCA4/BRG1 AND
CC       HDAC1 (By similarity). Interacts with PSMA3 and USP4. Interacts
CC       (when methylated at Lys-860) with L3MBTL1. Interacts with CHEK2;
CC       phosphorylates RB1. Interacts with CEBPA (PubMed:15107404).
CC       Interacts with adenovirus E1A protein, HPV E7 protein and SV40
CC       large T antigen. Interacts with human cytomegalovirus/HHV-5
CC       protein UL123. {ECO:0000250|UniProtKB:P13405,
CC       ECO:0000250|UniProtKB:P33568, ECO:0000269|PubMed:10409732,
CC       ECO:0000269|PubMed:10446990, ECO:0000269|PubMed:10779342,
CC       ECO:0000269|PubMed:10869426, ECO:0000269|PubMed:10888886,
CC       ECO:0000269|PubMed:11223246, ECO:0000269|PubMed:11484059,
CC       ECO:0000269|PubMed:11571652, ECO:0000269|PubMed:12450794,
CC       ECO:0000269|PubMed:12466551, ECO:0000269|PubMed:12475961,
CC       ECO:0000269|PubMed:12682072, ECO:0000269|PubMed:12695505,
CC       ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:15107404,
CC       ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589,
CC       ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959,
CC       ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886,
CC       ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038,
CC       ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128,
CC       ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:17996702,
CC       ECO:0000269|PubMed:20870719, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:7525595,
CC       ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8414517,
CC       ECO:0000269|PubMed:8892909, ECO:0000269|PubMed:9858607}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-491274, EBI-491274;
CC       P03070:- (xeno); NbExp=6; IntAct=EBI-491274, EBI-617698;
CC       P03255:- (xeno); NbExp=8; IntAct=EBI-491274, EBI-2603114;
CC       P03255-1:- (xeno); NbExp=2; IntAct=EBI-491274, EBI-6692439;
CC       P03255-2:- (xeno); NbExp=3; IntAct=EBI-491274, EBI-6859460;
CC       P24941:CDK2; NbExp=3; IntAct=EBI-491274, EBI-375096;
CC       P30285:Cdk4 (xeno); NbExp=2; IntAct=EBI-491274, EBI-847225;
CC       Q155P7:Cenpf (xeno); NbExp=4; IntAct=EBI-491274, EBI-2211248;
CC       O14757:CHEK1; NbExp=3; IntAct=EBI-491274, EBI-974488;
CC       O96017:CHEK2; NbExp=3; IntAct=EBI-491274, EBI-1180783;
CC       Q13574-2:DGKZ; NbExp=6; IntAct=EBI-491274, EBI-715527;
CC       Q13627:DYRK1A; NbExp=3; IntAct=EBI-491274, EBI-1053596;
CC       Q9Y463:DYRK1B; NbExp=3; IntAct=EBI-491274, EBI-634187;
CC       Q01094:E2F1; NbExp=20; IntAct=EBI-491274, EBI-448924;
CC       Q14209:E2F2; NbExp=3; IntAct=EBI-491274, EBI-718476;
CC       O00716:E2F3; NbExp=4; IntAct=EBI-491274, EBI-765551;
CC       A0MPS7:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-7014709;
CC       P03129:E7 (xeno); NbExp=21; IntAct=EBI-491274, EBI-866453;
CC       P04020:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-7005254;
CC       P06464:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-6944797;
CC       P06465:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-963841;
CC       P06788:E7 (xeno); NbExp=2; IntAct=EBI-491274, EBI-1776887;
CC       P42685:FRK; NbExp=3; IntAct=EBI-491274, EBI-1383583;
CC       P62993:GRB2; NbExp=4; IntAct=EBI-491274, EBI-401755;
CC       O60381:HBP1; NbExp=2; IntAct=EBI-491274, EBI-954175;
CC       Q13547:HDAC1; NbExp=4; IntAct=EBI-491274, EBI-301834;
CC       P52927:Hmga2 (xeno); NbExp=5; IntAct=EBI-491274, EBI-912574;
CC       Q9R002:Ifi202 (xeno); NbExp=5; IntAct=EBI-491274, EBI-3043899;
CC       Q14653:IRF3; NbExp=2; IntAct=EBI-491274, EBI-2650369;
CC       Q16539:MAPK14; NbExp=4; IntAct=EBI-491274, EBI-73946;
CC       Q00987:MDM2; NbExp=4; IntAct=EBI-491274, EBI-389668;
CC       O15151:MDM4; NbExp=4; IntAct=EBI-491274, EBI-398437;
CC       Q14686:NCOA6; NbExp=3; IntAct=EBI-491274, EBI-78670;
CC       P07197:NEFM; NbExp=2; IntAct=EBI-491274, EBI-1105035;
CC       Q8VSP9:ospF (xeno); NbExp=2; IntAct=EBI-491274, EBI-6506625;
CC       Q9UQ80:PA2G4; NbExp=4; IntAct=EBI-491274, EBI-924893;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-491274, EBI-357253;
CC       P55345:PRMT2; NbExp=3; IntAct=EBI-491274, EBI-78458;
CC       Q00577:PURA; NbExp=6; IntAct=EBI-491274, EBI-1045860;
CC       P04049:RAF1; NbExp=3; IntAct=EBI-491274, EBI-365996;
CC       O75150:RNF40; NbExp=3; IntAct=EBI-491274, EBI-744408;
CC       Q8WTS6:SETD7; NbExp=4; IntAct=EBI-491274, EBI-1268586;
CC       Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-491274, EBI-1802585;
CC       Q3TKT4:Smarca4 (xeno); NbExp=4; IntAct=EBI-491274, EBI-1210244;
CC       Q96PU4:UHRF2; NbExp=4; IntAct=EBI-491274, EBI-625304;
CC       Q93009:USP7; NbExp=8; IntAct=EBI-491274, EBI-302474;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}.
CC   -!- TISSUE SPECIFICITY: Expressed in the retina.
CC   -!- DOMAIN: The Pocket domain binds to the threonine-phosphorylated
CC       domain C, thereby preventing interaction with heterodimeric E2F/DP
CC       transcription factor complexes.
CC   -!- PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at
CC       Ser-567 in G1, thereby releasing E2F1 which is then able to
CC       activate cell growth. Dephosphorylated at the late M phase. SV40
CC       large T antigen, HPV E7 and adenovirus E1A bind to the
CC       underphosphorylated, active form of pRb. Phosphorylation at Thr-
CC       821 and Thr-826 promotes interaction between the C-terminal domain
CC       C and the Pocket domain, and thereby inhibits interactions with
CC       heterodimeric E2F/DP transcription factor complexes.
CC       Dephosphorylated at Ser-795 by calcineruin upon calcium
CC       stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and
CC       Ser-811 is required for G0-G1 transition. Phosphorylated by CDK1
CC       and CDK2 upon TGFB1-mediated apoptosis (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity).
CC       Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at
CC       Ser-807 and Ser-811, and promotes cell cycle progression.
CC       Monomethylation at Lys-860 by SMYD2 promotes interaction with
CC       L3MBTL1. {ECO:0000250, ECO:0000269|PubMed:10499802,
CC       ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340,
CC       ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128,
CC       ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719,
CC       ECO:0000269|PubMed:22787429, ECO:0000269|PubMed:8114739}.
CC   -!- PTM: Acetylation at Lys-873 and Lys-874 regulates subcellular
CC       localization, at least during keratinocytes differentiation.
CC       {ECO:0000269|PubMed:20940255}.
CC   -!- DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]:
CC       Congenital malignant tumor that arises from the nuclear layers of
CC       the retina. It occurs in about 1:20'000 live births and represents
CC       about 2% of childhood malignancies. It is bilateral in about 30%
CC       of cases. Although most RB appear sporadically, about 20% are
CC       transmitted as an autosomal dominant trait with incomplete
CC       penetrance. The diagnosis is usually made before the age of 2
CC       years when strabismus or a gray to yellow reflex from pupil ('cat
CC       eye') is investigated. {ECO:0000269|PubMed:10671068,
CC       ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883,
CC       ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558,
CC       ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327,
CC       ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116,
CC       ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452,
CC       ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy
CC       originating in tissues of the urinary bladder. It often presents
CC       with multiple tumors appearing at different times and at different
CC       sites in the bladder. Most bladder cancers are transitional cell
CC       carcinomas that begin in cells that normally make up the inner
CC       lining of the bladder. Other types of bladder cancer include
CC       squamous cell carcinoma (cancer that begins in thin, flat cells)
CC       and adenocarcinoma (cancer that begins in cells that make and
CC       release mucus and other fluids). Bladder cancer is a complex
CC       disorder with both genetic and environmental influences.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma
CC       originating in bone-forming cells, affecting the ends of long
CC       bones. Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the retinoblastoma protein (RB) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=RB1base; Note=RB1 mutation db;
CC       URL="http://rb1-lsdb.d-lohmann.de/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RB1ID90.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rb1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry;
CC       URL="http://en.wikipedia.org/wiki/Retinoblastoma_protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15400; AAA69807.1; ALT_SEQ; mRNA.
DR   EMBL; M28419; AAA69808.1; -; mRNA.
DR   EMBL; M33647; AAA69806.1; -; mRNA.
DR   EMBL; L41870; AAB59465.1; -; mRNA.
DR   EMBL; M27866; AAA53484.1; -; Genomic_DNA.
DR   EMBL; M27845; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27846; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27847; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27849; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27850; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27851; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L35146; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27852; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27853; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27854; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27855; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27856; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27857; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27858; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27859; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27860; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L35147; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27862; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27863; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27864; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; M27865; AAA53484.1; JOINED; Genomic_DNA.
DR   EMBL; L41889; AAB59467.1; -; Genomic_DNA.
DR   EMBL; L41890; AAA65735.1; -; Genomic_DNA.
DR   EMBL; L41891; AAA65736.1; -; Genomic_DNA.
DR   EMBL; L41893; AAA65737.1; -; Genomic_DNA.
DR   EMBL; L41894; AAA65738.1; -; Genomic_DNA.
DR   EMBL; L41895; AAA65739.1; -; Genomic_DNA.
DR   EMBL; L41896; AAA65740.1; -; Genomic_DNA.
DR   EMBL; L41897; AAA65741.1; -; Genomic_DNA.
DR   EMBL; L41898; AAB59471.1; -; Genomic_DNA.
DR   EMBL; L41899; AAB59473.1; -; Genomic_DNA.
DR   EMBL; L41997; AAB59482.1; -; Genomic_DNA.
DR   EMBL; X16439; CAA34462.1; -; Genomic_DNA.
DR   EMBL; AF551763; AAN64133.1; -; Genomic_DNA.
DR   EMBL; AK291258; BAF83947.1; -; mRNA.
DR   EMBL; AL136960; CAH70901.1; -; Genomic_DNA.
DR   EMBL; AL392048; CAH70901.1; JOINED; Genomic_DNA.
DR   EMBL; AL392048; CAH72243.1; -; Genomic_DNA.
DR   EMBL; AL136960; CAH72243.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08793.1; -; Genomic_DNA.
DR   EMBL; BC039060; AAH39060.1; -; mRNA.
DR   EMBL; BC040540; AAH40540.1; -; mRNA.
DR   EMBL; L11910; AAA53483.1; -; Genomic_DNA.
DR   CCDS; CCDS31973.1; -.
DR   PIR; JS0276; RBHU.
DR   RefSeq; NP_000312.2; NM_000321.2.
DR   UniGene; Hs.408528; -.
DR   PDB; 1AD6; X-ray; 2.30 A; A=378-562.
DR   PDB; 1GH6; X-ray; 3.20 A; B=379-577, B=645-772.
DR   PDB; 1GUX; X-ray; 1.85 A; A=372-589, B=636-787.
DR   PDB; 1H25; X-ray; 2.50 A; E=868-878.
DR   PDB; 1N4M; X-ray; 2.20 A; A/B=380-785.
DR   PDB; 1O9K; X-ray; 2.60 A; A/C/E/G=372-589, B/D/F/H=636-787.
DR   PDB; 1PJM; X-ray; 2.50 A; A=858-881.
DR   PDB; 2AZE; X-ray; 2.55 A; C=829-874.
DR   PDB; 2QDJ; X-ray; 2.00 A; A=52-355.
DR   PDB; 2R7G; X-ray; 1.67 A; A/C=380-787.
DR   PDB; 3N5U; X-ray; 3.20 A; C=870-882.
DR   PDB; 3POM; X-ray; 2.50 A; A/B=380-577, A/B=643-783.
DR   PDB; 4CRI; X-ray; 2.35 A; C/D=802-817.
DR   PDB; 4ELJ; X-ray; 2.70 A; A=53-787.
DR   PDB; 4ELL; X-ray; 1.98 A; A/B=380-787.
DR   PDBsum; 1AD6; -.
DR   PDBsum; 1GH6; -.
DR   PDBsum; 1GUX; -.
DR   PDBsum; 1H25; -.
DR   PDBsum; 1N4M; -.
DR   PDBsum; 1O9K; -.
DR   PDBsum; 1PJM; -.
DR   PDBsum; 2AZE; -.
DR   PDBsum; 2QDJ; -.
DR   PDBsum; 2R7G; -.
DR   PDBsum; 3N5U; -.
DR   PDBsum; 3POM; -.
DR   PDBsum; 4CRI; -.
DR   PDBsum; 4ELJ; -.
DR   PDBsum; 4ELL; -.
DR   ProteinModelPortal; P06400; -.
DR   SMR; P06400; 53-786, 829-872.
DR   BioGrid; 111860; 212.
DR   DIP; DIP-582N; -.
DR   IntAct; P06400; 106.
DR   MINT; MINT-98847; -.
DR   STRING; 9606.ENSP00000267163; -.
DR   BindingDB; P06400; -.
DR   ChEMBL; CHEMBL5288; -.
DR   DrugBank; DB00030; Insulin Regular.
DR   PhosphoSite; P06400; -.
DR   BioMuta; RB1; -.
DR   DMDM; 132164; -.
DR   MaxQB; P06400; -.
DR   PaxDb; P06400; -.
DR   PeptideAtlas; P06400; -.
DR   PRIDE; P06400; -.
DR   DNASU; 5925; -.
DR   Ensembl; ENST00000267163; ENSP00000267163; ENSG00000139687.
DR   GeneID; 5925; -.
DR   KEGG; hsa:5925; -.
DR   UCSC; uc001vcb.3; human.
DR   CTD; 5925; -.
DR   GeneCards; GC13P048877; -.
DR   GeneReviews; RB1; -.
DR   HGNC; HGNC:9884; RB1.
DR   HPA; CAB000095; -.
DR   HPA; CAB016687; -.
DR   MIM; 109800; phenotype.
DR   MIM; 180200; phenotype.
DR   MIM; 259500; phenotype.
DR   MIM; 614041; gene.
DR   neXtProt; NX_P06400; -.
DR   Orphanet; 357027; Familial retinoblastoma.
DR   Orphanet; 1587; Monosomy 13q14.
DR   Orphanet; 357034; Unilateral retinoblastoma.
DR   PharmGKB; PA295; -.
DR   eggNOG; NOG296920; -.
DR   GeneTree; ENSGT00530000063235; -.
DR   HOVERGEN; HBG008967; -.
DR   InParanoid; P06400; -.
DR   KO; K06618; -.
DR   OMA; QHTLQNE; -.
DR   OrthoDB; EOG7P5T04; -.
DR   PhylomeDB; P06400; -.
DR   TreeFam; TF105568; -.
DR   Reactome; REACT_1156; Orc1 removal from chromatin.
DR   Reactome; REACT_1574; Cyclin E associated events during G1/S transition.
DR   Reactome; REACT_169121; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; REACT_264303; Condensation of Prophase Chromosomes.
DR   Reactome; REACT_308; Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes.
DR   Reactome; REACT_329; Inhibition of replication initiation of damaged DNA by RB1/E2F1.
DR   Reactome; REACT_821; Cyclin D associated events in G1.
DR   Reactome; REACT_9029; Cyclin A:Cdk2-associated events at S phase entry.
DR   SignaLink; P06400; -.
DR   ChiTaRS; RB1; human.
DR   EvolutionaryTrace; P06400; -.
DR   GeneWiki; Retinoblastoma_protein; -.
DR   GenomeRNAi; 5925; -.
DR   NextBio; 23076; -.
DR   PMAP-CutDB; P06400; -.
DR   PRO; PR:P06400; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; P06400; -.
DR   CleanEx; HS_RB1; -.
DR   ExpressionAtlas; P06400; baseline and differential.
DR   Genevisible; P06400; HS.
DR   GO; GO:0000785; C:chromatin; TAS:ProtInc.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0035189; C:Rb-E2F complex; TAS:BHF-UCL.
DR   GO; GO:0005819; C:spindle; IEA:Ensembl.
DR   GO; GO:0016514; C:SWI/SNF complex; TAS:BHF-UCL.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IDA:UniProtKB.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:BHF-UCL.
DR   GO; GO:0000075; P:cell cycle checkpoint; TAS:ProtInc.
DR   GO; GO:0051301; P:cell division; IEA:Ensembl.
DR   GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; IEA:Ensembl.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; TAS:BHF-UCL.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0043353; P:enucleate erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0034349; P:glial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0034088; P:maintenance of mitotic sister chromatid cohesion; IMP:BHF-UCL.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; TAS:BHF-UCL.
DR   GO; GO:0045445; P:myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; TAS:BHF-UCL.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IPI:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; TAS:BHF-UCL.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0007070; P:negative regulation of transcription from RNA polymerase II promoter during mitosis; TAS:BHF-UCL.
DR   GO; GO:0071930; P:negative regulation of transcription involved in G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0042551; P:neuron maturation; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Ensembl.
DR   GO; GO:0045842; P:positive regulation of mitotic metaphase/anaphase transition; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0071459; P:protein localization to chromosome, centromeric region; IMP:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0090230; P:regulation of centromere complex assembly; TAS:BHF-UCL.
DR   GO; GO:0071922; P:regulation of cohesin localization to chromatin; IMP:BHF-UCL.
DR   GO; GO:0043550; P:regulation of lipid kinase activity; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S transition of mitotic cell cycle; TAS:BHF-UCL.
DR   GO; GO:0031134; P:sister chromatid biorientation; IMP:BHF-UCL.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.472.10; -; 2.
DR   InterPro; IPR013763; Cyclin-like.
DR   InterPro; IPR002720; RB_A.
DR   InterPro; IPR002719; RB_B.
DR   InterPro; IPR015030; RB_C.
DR   InterPro; IPR028309; RB_fam.
DR   InterPro; IPR024599; RB_N.
DR   PANTHER; PTHR13742; PTHR13742; 1.
DR   Pfam; PF11934; DUF3452; 1.
DR   Pfam; PF01858; RB_A; 1.
DR   Pfam; PF01857; RB_B; 1.
DR   Pfam; PF08934; Rb_C; 1.
DR   SMART; SM00385; CYCLIN; 1.
DR   SUPFAM; SSF47954; SSF47954; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Chromatin regulator;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   DNA-binding; Host-virus interaction; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P13405}.
FT   CHAIN         2    928       Retinoblastoma-associated protein.
FT                                /FTId=PRO_0000167836.
FT   REGION      373    771       Pocket; binds T and E1A.
FT   REGION      373    579       Domain A.
FT   REGION      580    639       Spacer.
FT   REGION      640    771       Domain B.
FT   REGION      763    928       Interaction with LIMD1.
FT   REGION      771    928       Domain C; mediates interaction with E4F1.
FT   MOTIF       870    876       Nuclear localization signal.
FT                                {ECO:0000305}.
FT   COMPBIAS     10     18       Poly-Ala.
FT   COMPBIAS     20     29       Poly-Pro.
FT   MOD_RES       2      2       N,N-dimethylproline.
FT                                {ECO:0000250|UniProtKB:P13405}.
FT   MOD_RES      37     37       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     249    249       Phosphoserine; by CDK1.
FT                                {ECO:0000269|PubMed:1756735,
FT                                ECO:0000269|PubMed:18220336,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     252    252       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:1756735,
FT                                ECO:0000269|PubMed:18220336,
FT                                ECO:0000269|PubMed:18669648}.
FT   MOD_RES     356    356       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18220336}.
FT   MOD_RES     373    373       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:1756735,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     567    567       Phosphoserine; by CDK2.
FT                                {ECO:0000269|PubMed:10499802}.
FT   MOD_RES     612    612       Phosphoserine; by CHEK2 and CHEK1.
FT                                {ECO:0000269|PubMed:17380128,
FT                                ECO:0000269|PubMed:18669648}.
FT   MOD_RES     795    795       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P33568}.
FT   MOD_RES     807    807       Phosphoserine; by CDK1 and CDK3.
FT                                {ECO:0000269|PubMed:15084261,
FT                                ECO:0000269|PubMed:1756735,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     810    810       N6-methyllysine; by SMYD2.
FT                                {ECO:0000269|PubMed:22787429}.
FT   MOD_RES     811    811       Phosphoserine; by CDK1 and CDK3.
FT                                {ECO:0000269|PubMed:15084261,
FT                                ECO:0000269|PubMed:1756735,
FT                                ECO:0000269|PubMed:18669648}.
FT   MOD_RES     821    821       Phosphothreonine; by CDK6.
FT                                {ECO:0000269|PubMed:15809340,
FT                                ECO:0000269|PubMed:16360038,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     823    823       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     826    826       Phosphothreonine; by CDK4.
FT                                {ECO:0000269|PubMed:15809340,
FT                                ECO:0000269|PubMed:16360038,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     841    841       Phosphothreonine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     860    860       N6-methyllysine; by SMYD2.
FT                                {ECO:0000269|PubMed:20870719}.
FT   MOD_RES     873    873       N6-acetyllysine; by PCAF.
FT                                {ECO:0000269|PubMed:20940255}.
FT   MOD_RES     874    874       N6-acetyllysine; by PCAF.
FT                                {ECO:0000269|PubMed:20940255}.
FT   VARIANT      72     72       E -> Q (in RB).
FT                                {ECO:0000269|PubMed:8605116}.
FT                                /FTId=VAR_005572.
FT   VARIANT     133    133       N -> H (in dbSNP:rs3092900).
FT                                /FTId=VAR_051909.
FT   VARIANT     137    137       E -> D (in RB; unilateral form).
FT                                {ECO:0000269|PubMed:9311732}.
FT                                /FTId=VAR_005573.
FT   VARIANT     173    173       Y -> H. {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069376.
FT   VARIANT     185    185       I -> T (in RB).
FT                                {ECO:0000269|PubMed:7795591}.
FT                                /FTId=VAR_005574.
FT   VARIANT     310    310       G -> E (in RB; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:9973307}.
FT                                /FTId=VAR_010045.
FT   VARIANT     358    358       R -> G (in RB).
FT                                {ECO:0000269|PubMed:8776589}.
FT                                /FTId=VAR_010046.
FT   VARIANT     358    358       R -> Q (in RB).
FT                                /FTId=VAR_005575.
FT   VARIANT     436    436       Q -> K (in dbSNP:rs4151534).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019379.
FT   VARIANT     447    447       K -> Q (in RB).
FT                                {ECO:0000269|PubMed:9140452}.
FT                                /FTId=VAR_010048.
FT   VARIANT     457    457       M -> R (in RB).
FT                                {ECO:0000269|PubMed:8346255}.
FT                                /FTId=VAR_005576.
FT   VARIANT     480    480       Missing (in RB; mild form).
FT                                {ECO:0000269|PubMed:7927327}.
FT                                /FTId=VAR_005577.
FT   VARIANT     500    500       R -> G (in RB).
FT                                {ECO:0000269|PubMed:11524739}.
FT                                /FTId=VAR_011580.
FT   VARIANT     525    525       A -> G (in dbSNP:rs4151539).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019380.
FT   VARIANT     530    530       K -> R (in RB).
FT                                {ECO:0000269|PubMed:7704558}.
FT                                /FTId=VAR_010049.
FT   VARIANT     549    549       H -> Y (in RB).
FT                                {ECO:0000269|PubMed:8605116}.
FT                                /FTId=VAR_005578.
FT   VARIANT     567    567       S -> L (in RB).
FT                                {ECO:0000269|PubMed:10671068,
FT                                ECO:0000269|PubMed:2594029}.
FT                                /FTId=VAR_005579.
FT   VARIANT     569    569       L -> F (in dbSNP:rs3092895).
FT                                /FTId=VAR_051910.
FT   VARIANT     616    616       K -> E (in RB).
FT                                {ECO:0000269|PubMed:11524739}.
FT                                /FTId=VAR_011581.
FT   VARIANT     635    635       A -> P (in RB).
FT                                {ECO:0000269|PubMed:7795591}.
FT                                /FTId=VAR_005580.
FT   VARIANT     654    654       V -> E (in RB).
FT                                {ECO:0000269|PubMed:7795591}.
FT                                /FTId=VAR_005581.
FT   VARIANT     657    657       L -> P (in RB).
FT                                {ECO:0000269|PubMed:8776589}.
FT                                /FTId=VAR_010050.
FT   VARIANT     661    661       R -> W (in RB; mild form).
FT                                {ECO:0000269|PubMed:1352883,
FT                                ECO:0000269|PubMed:7927327,
FT                                ECO:0000269|PubMed:8776589,
FT                                ECO:0000269|PubMed:9311732}.
FT                                /FTId=VAR_005582.
FT   VARIANT     662    662       L -> P (in RB).
FT                                {ECO:0000269|PubMed:10671068}.
FT                                /FTId=VAR_005583.
FT   VARIANT     673    673       H -> P (in RB).
FT                                /FTId=VAR_005584.
FT   VARIANT     685    685       Q -> P (in RB).
FT                                {ECO:0000269|PubMed:7795591}.
FT                                /FTId=VAR_005585.
FT   VARIANT     697    697       D -> E (in dbSNP:rs3092903).
FT                                /FTId=VAR_051911.
FT   VARIANT     706    706       C -> Y (in RB).
FT                                /FTId=VAR_005586.
FT   VARIANT     712    712       C -> R (in RB).
FT                                {ECO:0000269|PubMed:10671068}.
FT                                /FTId=VAR_005587.
FT   VARIANT     746    746       E -> G (in dbSNP:rs3092905).
FT                                /FTId=VAR_034442.
FT   VARIANT     803    803       N -> K (in RB).
FT                                {ECO:0000269|PubMed:8605116}.
FT                                /FTId=VAR_005588.
FT   MUTAGEN     821    821       T->A: Abolishes interaction with Pocket
FT                                domain; when associated with A-826.
FT                                {ECO:0000269|PubMed:16360038}.
FT   MUTAGEN     826    826       T->A: Abolishes interaction with Pocket
FT                                domain; when associated with A-821.
FT                                {ECO:0000269|PubMed:16360038}.
FT   MUTAGEN     860    860       K->R: Abolishes monomethylation by SMYD2
FT                                and subsequent interaction with L3MBTL1.
FT                                {ECO:0000269|PubMed:20870719}.
FT   MUTAGEN     870    870       K->R: Does not affect the ability to be
FT                                methylated by SMYD2; when associated with
FT                                873-R-R-874.
FT                                {ECO:0000269|PubMed:20870719}.
FT   MUTAGEN     873    874       KK->R: Does not affect the ability to be
FT                                methylated by SMYD2; when associated with
FT                                873-R-R-874.
FT                                {ECO:0000269|PubMed:20870719,
FT                                ECO:0000269|PubMed:20940255}.
FT   MUTAGEN     873    874       KK->RR: Does not alter Rb localization in
FT                                cycling cells, but mislocalizes to the
FT                                cytoplasm during keratinocytes
FT                                differentiation.
FT                                {ECO:0000269|PubMed:20870719,
FT                                ECO:0000269|PubMed:20940255}.
FT   CONFLICT    500    501       RS -> SN (in Ref. 7; AAN64133).
FT                                {ECO:0000305}.
FT   HELIX        55     63       {ECO:0000244|PDB:2QDJ}.
FT   HELIX        68     82       {ECO:0000244|PDB:2QDJ}.
FT   HELIX        95    110       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       117    124       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       128    135       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       142    172       {ECO:0000244|PDB:2QDJ}.
FT   STRAND      180    182       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       188    204       {ECO:0000244|PDB:2QDJ}.
FT   STRAND      207    209       {ECO:0000244|PDB:4ELJ}.
FT   HELIX       212    228       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       232    234       {ECO:0000244|PDB:2QDJ}.
FT   TURN        237    240       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       241    243       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       272    281       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       285    294       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       296    299       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       302    306       {ECO:0000244|PDB:4ELJ}.
FT   HELIX       314    328       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       333    338       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       341    343       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       347    353       {ECO:0000244|PDB:2QDJ}.
FT   HELIX       382    391       {ECO:0000244|PDB:2R7G}.
FT   HELIX       398    405       {ECO:0000244|PDB:2R7G}.
FT   STRAND      407    409       {ECO:0000244|PDB:2R7G}.
FT   HELIX       412    434       {ECO:0000244|PDB:2R7G}.
FT   HELIX       436    438       {ECO:0000244|PDB:2R7G}.
FT   HELIX       439    468       {ECO:0000244|PDB:2R7G}.
FT   HELIX       474    477       {ECO:0000244|PDB:2R7G}.
FT   HELIX       480    501       {ECO:0000244|PDB:2R7G}.
FT   TURN        504    506       {ECO:0000244|PDB:1N4M}.
FT   STRAND      511    513       {ECO:0000244|PDB:4ELJ}.
FT   HELIX       516    521       {ECO:0000244|PDB:2R7G}.
FT   HELIX       525    529       {ECO:0000244|PDB:2R7G}.
FT   HELIX       532    538       {ECO:0000244|PDB:2R7G}.
FT   HELIX       544    559       {ECO:0000244|PDB:2R7G}.
FT   HELIX       561    563       {ECO:0000244|PDB:2R7G}.
FT   STRAND      564    566       {ECO:0000244|PDB:4ELJ}.
FT   HELIX       569    577       {ECO:0000244|PDB:2R7G}.
FT   HELIX       582    586       {ECO:0000244|PDB:4ELL}.
FT   HELIX       602    607       {ECO:0000244|PDB:4ELL}.
FT   HELIX       645    669       {ECO:0000244|PDB:2R7G}.
FT   HELIX       676    690       {ECO:0000244|PDB:2R7G}.
FT   HELIX       692    695       {ECO:0000244|PDB:2R7G}.
FT   HELIX       700    714       {ECO:0000244|PDB:2R7G}.
FT   HELIX       721    728       {ECO:0000244|PDB:2R7G}.
FT   STRAND      731    733       {ECO:0000244|PDB:1N4M}.
FT   HELIX       737    740       {ECO:0000244|PDB:2R7G}.
FT   STRAND      741    743       {ECO:0000244|PDB:2R7G}.
FT   STRAND      745    747       {ECO:0000244|PDB:2R7G}.
FT   STRAND      748    750       {ECO:0000244|PDB:4ELJ}.
FT   HELIX       752    758       {ECO:0000244|PDB:2R7G}.
FT   HELIX       760    770       {ECO:0000244|PDB:2R7G}.
FT   STRAND      773    775       {ECO:0000244|PDB:2R7G}.
FT   STRAND      830    836       {ECO:0000244|PDB:2AZE}.
FT   TURN        838    840       {ECO:0000244|PDB:2AZE}.
FT   HELIX       841    853       {ECO:0000244|PDB:2AZE}.
SQ   SEQUENCE   928 AA;  106159 MW;  C8E746111E19CC32 CRC64;
     MPPKTPRKTA ATAAAAAAEP PAPPPPPPPE EDPEQDSGPE DLPLVRLEFE ETEEPDFTAL
     CQKLKIPDHV RERAWLTWEK VSSVDGVLGG YIQKKKELWG ICIFIAAVDL DEMSFTFTEL
     QKNIEISVHK FFNLLKEIDT STKVDNAMSR LLKKYDVLFA LFSKLERTCE LIYLTQPSSS
     ISTEINSALV LKVSWITFLL AKGEVLQMED DLVISFQLML CVLDYFIKLS PPMLLKEPYK
     TAVIPINGSP RTPRRGQNRS ARIAKQLEND TRIIEVLCKE HECNIDEVKN VYFKNFIPFM
     NSLGLVTSNG LPEVENLSKR YEEIYLKNKD LDARLFLDHD KTLQTDSIDS FETQRTPRKS
     NLDEEVNVIP PHTPVRTVMN TIQQLMMILN SASDQPSENL ISYFNNCTVN PKESILKRVK
     DIGYIFKEKF AKAVGQGCVE IGSQRYKLGV RLYYRVMESM LKSEEERLSI QNFSKLLNDN
     IFHMSLLACA LEVVMATYSR STSQNLDSGT DLSFPWILNV LNLKAFDFYK VIESFIKAEG
     NLTREMIKHL ERCEHRIMES LAWLSDSPLF DLIKQSKDRE GPTDHLESAC PLNLPLQNNH
     TAADMYLSPV RSPKKKGSTT RVNSTANAET QATSAFQTQK PLKSTSLSLF YKKVYRLAYL
     RLNTLCERLL SEHPELEHII WTLFQHTLQN EYELMRDRHL DQIMMCSMYG ICKVKNIDLK
     FKIIVTAYKD LPHAVQETFK RVLIKEEEYD SIIVFYNSVF MQRLKTNILQ YASTRPPTLS
     PIPHIPRSPY KFPSSPLRIP GGNIYISPLK SPYKISEGLP TPTKMTPRSR ILVSIGESFG
     TSEKFQKINQ MVCNSDRVLK RSAEGSNPPK PLKKLRFDIE GSDEADGSKH LPGESKFQQK
     LAEMTSTRTR MQKQKMNDSM DTSNKEEK
//
